Keros Therapeutics (NASDAQ:KROS) Given “Buy” Rating at HC Wainwright

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently have a $100.00 price objective on the stock. HC Wainwright’s price objective would indicate a potential upside of 124.32% from the company’s current price.

Several other equities research analysts have also weighed in on KROS. Truist Financial reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $105.00 price target on shares of Keros Therapeutics in a research report on Wednesday, March 27th. William Blair reaffirmed an “outperform” rating on shares of Keros Therapeutics in a research report on Wednesday, February 21st. Finally, Wedbush reissued an “outperform” rating and set a $86.00 target price on shares of Keros Therapeutics in a research note on Thursday, February 29th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics has an average rating of “Buy” and a consensus target price of $86.00.

Keros Therapeutics Trading Down 9.7 %

Shares of NASDAQ:KROS opened at $44.58 on Tuesday. The firm’s 50 day moving average is $53.73 and its two-hundred day moving average is $53.75. The firm has a market capitalization of $1.61 billion, a P/E ratio of -8.66 and a beta of 1.25. Keros Therapeutics has a 52 week low of $27.02 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, May 8th. The company reported ($1.21) EPS for the quarter, beating the consensus estimate of ($1.33) by $0.12. The business had revenue of $0.08 million during the quarter. During the same quarter in the prior year, the company posted ($1.26) EPS. Keros Therapeutics’s revenue for the quarter was down 97.3% compared to the same quarter last year. Analysts predict that Keros Therapeutics will post -4.97 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 1.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,149 shares of the company’s stock worth $870,000 after buying an additional 251 shares during the last quarter. Ameritas Investment Partners Inc. boosted its stake in shares of Keros Therapeutics by 14.5% during the 1st quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares in the last quarter. Principal Financial Group Inc. increased its holdings in shares of Keros Therapeutics by 8.8% during the 1st quarter. Principal Financial Group Inc. now owns 7,063 shares of the company’s stock valued at $468,000 after acquiring an additional 574 shares during the last quarter. American International Group Inc. raised its stake in shares of Keros Therapeutics by 13.1% in the 1st quarter. American International Group Inc. now owns 12,653 shares of the company’s stock valued at $838,000 after acquiring an additional 1,465 shares in the last quarter. Finally, ProShare Advisors LLC lifted its holdings in Keros Therapeutics by 26.5% in the 1st quarter. ProShare Advisors LLC now owns 7,136 shares of the company’s stock worth $472,000 after purchasing an additional 1,496 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.